2.43
-0.01(-0.41%)
Currency In USD
| Previous Close | 2.44 |
| Open | 2.41 |
| Day High | 2.47 |
| Day Low | 2.41 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.87 |
| Volume | 4,764 |
| Average Volume | 32,073 |
| Market Cap | 21.28M |
| PE | -1.09 |
| EPS | -2.23 |
| Moving Average 50 Days | 2.41 |
| Moving Average 200 Days | 2.54 |
| Change | -0.01 |
If you invested $1000 in Lisata Therapeutics, Inc. (LSTA) 10 years ago, it would be worth $12.37 as of October 20, 2025 at a share price of $2.43. Whereas If you bought $1000 worth of Lisata Therapeutics, Inc. (LSTA) shares 5 years ago, it would be worth $96.43 as of October 20, 2025 at a share price of $2.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lisata Therapeutics to Present at LD Micro Main Event XIX
Newsfile
Oct 13, 2025 12:00 PM GMT
Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) - Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
GlobeNewswire Inc.
Oct 08, 2025 12:30 PM GMT
Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study results provide proof-of-concept support for leveragi
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (N